Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Breast Cancer
•
Medical Oncology
•
Breast Cancer, Metastatic
Given recent data would you offer cdk4/6 inhibitor in addition to AI or fulvestrant to metastatic HR+, HER2- and BRCA +?
Related Questions
What is your recommended treatment sequencing strategy in patients with HER2+ breast cancer and leptomeningeal carcinomatosis?
What is your experience and treatment efficacy of tucatinib if used after enhertu in metastatic breast cancer?
How would you approach a patient with metastatic high grade neuroendocrine carcinoma of the breast which is HR+ HER2 negative?
Is there any benefit of anastrozole in addition to fulvestrant and palbociclib in a patient with HR+ metastatic breast cancer?
What are your top takeaways in Radiation Oncology from SABCS 2024?
What are your top takeaways in Breast Cancer from ESMO 2024?
What are your top takeaways in Breast Cancer from ASTRO 2024?
Is there a correlation with severity of rash as an adverse event and response rate with capivasertib?
What are your top takeaways in Medical Oncology from SABCS 2024?
Do you use breast MRI or ultrasound to assess tumor size prior to neoadjuvant chemotherapy in breast cancer?
